Scientific Board

Andrew D. Hamilton, PhD
A world-wide renown chemist expert in peptidomimetics. Hamilton’s research has spanned porphyrin, supramolecular, medicinal and chemical biology. During 2004-2008 he was Provost of Yale University. Since 2009, Dr. Hamilton has been the Vice-Chancellor of the University of Oxford. In 2016, he was appointed 16th President of the New York University.

Enrique M. Ocio, PhD, MD
Deputy Medical Hematology Service of the University Hospital of Salamanca. A translational clinician expert in haematological neoplasias. Responsible of development of new antitumor drugs from preclinical to clinical trials in early phases, with a focus on multiple myeloma. Principal investigator in more than 15 clinical trials and responsible of 5 international clinical trials.

Evarist Feliu, MD
Prof. Feliu worked in the Department of Hematology of Barcelona Clínic Hospital from 1971 to 1991 under the Direction of Profs. C. Rozman and JL. Vives-Corrons. In 1991 joined the Germans Trias i Pujol Hospital as Head of the Hematology Service in 1991. He has been a center director and scientific director at the Catalan Institute of Oncology (ICO), where he is currently Head of the Hematology Laboratory Service.

José M López-Picazo, PhD, MD
Medical Oncologist at University Clinic of Navarra and assistant Professor at Medical School of the University of Navarra, Spain, with main dedication to lung cancer and head and neck cancer. As a researcher he has focused on predictive and prognostic factors aimed at precision oncology practice. He has been principal investigator in more than 20 clinical trials, including new drugs or combination therapies.

Fernando Lecanda, PhD, Professor (University of Navarra).
Graduated in Pharmacy and Ph.D. in Physiology. Dr. Lecanda is Head of the Adhesion and Metastasis Laboratory at the Center for Applied Medical Research (CIMA) and Full Professor in Cell Biology (University of Navarra. In the past 15 years he has focused on the mechanisms of lung cancer bone metastases.